STAAR

Foley's Annual MLK Jr. Oratory Competition Announces 2022 Winners

Retrieved on: 
Saturday, January 15, 2022 - 12:34am

"This year's MLK Jr. Oratory Competition marks the 30th anniversary of the event in Dallas a truly momentous occasion for our law firm," said Michael Newman , Managing Partner of Foley's Dallas office.

Key Points: 
  • "This year's MLK Jr. Oratory Competition marks the 30th anniversary of the event in Dallas a truly momentous occasion for our law firm," said Michael Newman , Managing Partner of Foley's Dallas office.
  • "We host this competition to encourage our community to commemorate Dr. King's remarkable life and to pay tribute to his enduring legacy.
  • The event's success led to the establishment of the Houston competition in 1997 and the Chicago competition in 2020.
  • To learn more about Foley's MLK Jr. Oratory Competition, click here .

STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results

Retrieved on: 
Monday, January 10, 2022 - 12:00pm

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided preliminary results for the fourth quarter and fiscal year ended December 31, 2021.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided preliminary results for the fourth quarter and fiscal year ended December 31, 2021.
  • GAAP earnings per share is expected to be approximately $0.10 for the fourth quarter and approximately $0.50 for the fiscal year ended December 31, 2021.
  • STAARs preliminary sales results for fiscal 2021 highlight the robust demand for our lenses as our ICLs are elevated within the ophthalmic community.
  • STAAR expects to report complete fourth quarter and fiscal year results on or about February 23 and provided todays information due to investor meetings taking place January 10-11, 2022.

Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, November 4, 2021 - 1:05pm

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.
  • We are delighted to share clinical data and business updates across several programs demonstrating that Sangamo has three important assets progressing toward late-stage development.
  • We are energized by this momentum and look forward to continued execution of our corporate strategy, said Sandy Macrae, Chief Executive Officer of Sangamo.
  • Based on the STAAR study results to date, we have initiated planning for a Phase 3 Fabry disease clinical trial.

Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

Retrieved on: 
Thursday, November 4, 2021 - 12:00pm

Activity of 2-fold to 15-fold above mean normal was observed at last measurement as of the cutoff date.

Key Points: 
  • Activity of 2-fold to 15-fold above mean normal was observed at last measurement as of the cutoff date.
  • A presentation containing additional details about the study and these results is available on the Events & Presentations page of Sangamos website.
  • Sangamo expects to provide updated results from the STAAR study throughout 2022 and present these results at a medical meeting.
  • Based on STAAR study results to date, Sangamo has initiated planning for a Phase 3 clinical trial.

BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors

Their election to the Board will take effect in the event the Companys pending registration statement becomes effective.

Key Points: 
  • Their election to the Board will take effect in the event the Companys pending registration statement becomes effective.
  • Our new board member nominations represent qualified and diverse executives who bring new perspectives, relevant expertise and leadership experience, positioning BioRestorative to fulfill our mission of bringing cell therapies to patients said Lance Alstodt, Chief Executive Officer of BioRestorative.
  • Patrick F. Williams has more than 20 years of experience across medical device, consumer product goods and technology sectors.
  • BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

STAAR Surgical to Report Third Quarter Results on November 3, 2021

Retrieved on: 
Wednesday, October 20, 2021 - 12:00pm

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 1, 2021 on Wednesday, November 3, 2021 after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 1, 2021 on Wednesday, November 3, 2021 after the market close.
  • STAAR will host a conference call and webcast on Wednesday, November 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call (Access Code 249252), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

Texas Education Agency Approves FEV Tutor as a Full-Service Provider in New Statewide High-Impact Tutoring Initiative

Retrieved on: 
Tuesday, September 7, 2021 - 7:05pm

WOBURN, Mass., Sept. 7, 2021 /PRNewswire-PRWeb/ --The Texas Education Agency (TEA) has approved FEV Tutor to be a full-service member of the state's new Vetted Texas Tutoring Corps (VTTC).

Key Points: 
  • WOBURN, Mass., Sept. 7, 2021 /PRNewswire-PRWeb/ --The Texas Education Agency (TEA) has approved FEV Tutor to be a full-service member of the state's new Vetted Texas Tutoring Corps (VTTC).
  • Full-service VTTC members, like FEV Tutor, will provide end-to-end services, including instructional materials, tutoring platforms and trained tutors.
  • Based in Boston, FEV Tutor is the leading research and evidence-based online tutoring platform working nationally to effect change in K-12 education.
  • FEV Tutor leverages technology to deliver 1:1 high-impact and transformative personalized learning pathways through live, virtual tutoring sessions.

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

Retrieved on: 
Tuesday, August 10, 2021 - 2:00pm

Sydnexis, Inc., a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.

Key Points: 
  • Sydnexis, Inc., a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
  • Sydnexis STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia.
  • In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.
  • With more than 95 years of collective experience, Bluestem Capital is a private equity and venture capital firm currently with 25 portfolio companies.